Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in carbapenems.

Giovanni Bonfiglio1, Giovanni Russo, Giuseppe Nicoletti

  • 1Dipartimento di Scienze Microbiologiche, Università di Catania, Via Androne 81, 95124, Catania, Italy. bonfigio@mbox.unict.it

Expert Opinion on Investigational Drugs
|April 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A possible microvascular vulnerability in carotid artery dissection: insights from nailfold capillaroscopy.

Angiogenesis·2026
Same author

Similarity Matching Networks: Hebbian Learning and Convergence Over Multiple Timescales.

Neural computation·2026
Same author

Solar purpura preceding Raynaud's phenomenon in limited systemic sclerosis.

Internal and emergency medicine·2026
Same author

Distributionally robust free energy principle for decision-making.

Nature communications·2025
Same author

Iliolumbar pain attributable to ligamentous calcification in a man with psoriasis.

Zeitschrift fur Rheumatologie·2025
Same author

Feasibility and Safety of a Three-Dimensional Sheath for Right Ventricular Septal Endomyocardial Biopsy.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Carbapenems are broad-spectrum antibiotics crucial for treating severe infections. While generally stable against beta-lactamases, emerging resistance necessitates ongoing monitoring for effective use.

Area of Science:

  • Antibiotic resistance
  • Microbiology
  • Pharmacology

Background:

  • Carbapenems are a class of beta-lactam antibiotics known for their broad antibacterial spectrum.
  • The first carbapenem, imipenem, required coadministration with cilastatin due to hydrolysis by renal dehydropeptidase I.
  • Meropenem offered improved stability against this enzyme, paving the way for other carbapenem derivatives.

Purpose of the Study:

  • To review the characteristics and clinical significance of carbapenem antibiotics.
  • To highlight the spectrum of activity and stability of carbapenems against various beta-lactamases.
  • To discuss the emergence of carbapenem resistance and its implications for therapy.

Main Methods:

  • Literature review of carbapenem antibiotics.

Related Experiment Videos

  • Analysis of carbapenem structure-activity relationships.
  • Examination of carbapenemase enzyme profiles and resistance mechanisms.

    • Main Results:

    • Carbapenems exhibit ultra-broad-spectrum activity and stability against most clinically relevant beta-lactamases.
    • Class B beta-lactamases, including plasmid-mediated metallo-beta-lactamases, can hydrolyze carbapenems.
    • Emerging resistance, particularly from plasmid-borne enzymes in key pathogens, is a growing concern.

    Conclusions:

    • Carbapenems are vital first-line agents for severe infections due to their efficacy and safety profile.
    • The increasing prevalence of carbapenemases poses a significant threat to their continued utility.
    • Continued surveillance and development of new strategies are essential to combat carbapenem resistance.